keyboard_arrow_up

PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update is a new market research publication announced by Reportstack. The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Several pharmaceutical companies, including Biogen Idec, Novo Nordisk, Bayer, Baxter and CSL Behring, will be launching long-acting rFVIII and rFIX therapies that aim to address this unmet need by providing increased protein half-life that potentially extends the time between prophylactic doses. The emergence of these new products, beginning in 2014 in the US and 2015 in the 5EU, will have a drastic effect on the hemophilia A and B treatment landscapes in the 7MM as patients adopt these premium-priced products. This sea change will be lead by Biogen Idec’s Alprolix and Eloctate, which launched in the US in March and June 2014. Furthermore, Biogen’s competitive pricing strategy for their new agents will encourage patient-switching and influence pricing that their competitors will be able to adopt. In the developing markets of Argentina and China, economic barriers prevent widespread adoption of recombinant prophylactic regimens, and pharmaceutical companies will face additional challenges in penetrating these markets during the forecast period.

Highlights

Key Findings

- Long-acting recombinant FVIII and FIX replacement therapies will displace the established short-acting products in the 7MM over the forecast period.
- Biogen Idec’s competitive pricing strategy for their first-to-market long-acting rFVIII and rFIX products will impact overall pricing and market growth during the forecast period.
- The emerging long-acting recombinant therapies are poorly differentiated in terms of clinical benefit. Therefore, it is believed that time to market will play an important role in shaping market dynamics and that products that are able to launch ahead of the competition will have a significant advantage in gaining patient share.
- There is significant opportunity for new players in the hemophilia A and B markets such as Biogen Idec and Novo Nordisk to challenge established players Baxter, Bayer, CSL Behring and Pfizer.
- The levels of unmet needs among hemophilia patients in the US and 5EU are relatively low, although it believes that additional opportunity will remain for products that further extend the dosing interval beyond the extension offered by the pipeline agents. This is especially true for the long-acting FVIII therapies, which only offer a modest potential reduction in weekly prophylactic infusion schedules over the currently marketed products.
- The level of unmet need in the developing markets of Argentina and China is much higher than in the 7MM. In these markets, the greatest needs are for increased access to expensive recombinant prophylactic therapy, and those companies that can invest in infrastructure to improve patient access will have the greatest success in penetrating these markets.

Scope

- Overview of hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized hemophilia A and B (including inhibitor patients) therapeutics market revenue, annual cost of therapy and treatment usage pattern data by patient segment forecast from 2012 to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the hemophilia therapeutics market
- Pipeline analysis: The hemophilia pipeline is robust, with many late-stage candidates set to launch in the forecast period. The most promising 12 candidates in Phase III development are highlighted and profiled.
- Analysis of the current and future market competition in the global hemophilia A and B markets, including insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Major markets covered are US, France, Germany, Italy, Spain, UK, and Japan.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global hemophilia A and B recombinant therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia recombinant therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Forecast drug sales in the global hemophilia recombinant therapeutics market from 2012-2022.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.


Companies Mentioned

Baxter Biogen Idec Novo Nordisk CSL Behring Bayer Pfizer